



FROM LAB TO MANUFACTURING

Jason Benedict, BIOVIA CEO
Tom Doyle, MEDIDATA CTO



3DEXPERIENCE™



BIOPHARMACEUTICALS | BUSINESS DRIVERS



COMPLEXITY
Of new product classes



SPEED TO MARKET
Clinical & Manufacturing



PRECISION RELEASE
Same Day Release



COST PRESSURE



REGULATORY PRESSURE



SUSTAINABILITY
Mandate

BIOPHARMA | CURRENT CHALLENGES

Drug Candidate

IND

NDA

APR

Develop

Supply, Manufacture & Control

Research & Discovery

Preclinical


Clinical Development & Supply

Commercial Manufacturing


Phase 1

Phase 2

Phase 3



Faster to IND
Speed to Patient



Clinical Development
Patient Outcomes



Manufacturing
Right First Time & Efficient Release


BIOPHARMA | VIRTUAL TWIN EXPERIENCES

Combine Real World Data with Models to Deliver Outcomes



Patient Virtual Twin


Clinical Trial | Cohort
Organ | Tissue



The Living Heart Project


Product Virtual Twin

Molecule | Formulation
Device | System Architecture



Process Virtual Twin

Recipe | Method | Operations
Process Parameters | Controls



Plant Virtual Twin

Building | Environment
Equipment | Resources



Product fit for the Patient, Process fit for the Product, Plant fit for the Process

BIOPHARMA | LAB TO PLANT



CDMOs: Contract Development and Manufacturing Organizations

Enterprise

Collaboration

Quality

Regulatory

Compliance


Knowledge Capitalization

.../...



BIOPHARMA | GENAI EXPERIENCES FOR DISCOVERY

Small Molecule | Biologics | Cell Therapies



DISCOVERY STUDIO SIMULATION

Generative Design of a Biologic with RFDiffusion and ProteinMPNN




Leveraging advanced MODSIM + AI to Accelerate Cycle Times, Optimize Efficacy and Safety, and Improve Clinical Outcomes

BIOPHARMA | CLINICAL ACCELERATION

Data Availability

Phase III trials now collect **three times more** data than 10 years ago



About **75%** of that data is now collected **outside of EDC**



Rave Lite expands our reach in EDC to early and late phase studies while new AI capabilities and EHR connectivity solidify our base accelerating study build and site data collection. This together with new data acquisition experiences allows Medidata to capture a larger share of the overall trial data.

BIOPHARMA | CLINICAL ACCELERATION



Study Startup



Leveraging AI to design, simulate, and execute faster more efficient clinical trials benchmarked with historical trials and automating study build steps accelerating time to site to first-patient-in.

BIOPHARMA | CLINICAL ACCELERATION

Clinical Data Science



Faster signal detection leveraging AI to automatically identify anomalies and manage and increasing complex ecosystem of data.

CLINICAL RESEARCH

Challenges

Manual data reconciliation; reliance on siloed data stores; difficulty accessing operational data to optimize planning.

Solution

A single data management experience using MEDIDATA Clinical Data Studio

Value

Break down data silos and seamlessly integrate into our current software stack

Process diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources



PHARMACEUTICAL DEVELOPMENT

Challenges

Manual data handling; data not available for planning/ decisions; information buried in scattered documents; knowledge kept at individual level; excessive late-stage lab work.

Solution

A single CMC lab informatics solution using BIOVIA ONE Lab

Value

Accelerated development and tech transfer with S88-complaint procedures

Automated lab processes with streamlined data acquisition

Eliminated redundant work with better knowledge-sharing



DEVELOPMENT SCIENTIST

BIOPHARMA | FUTURE OF MANUFACTURING

Virtual Twin Experiences of Process and Plant

Accelerate new facility & product launches



Achieve more agile and flexible manufacturing



Achieve Net-Zero Carbon objectives



Produce **several drugs simultaneously**, versus only one in current industrial sites.



Take **days instead of weeks** to switch from manufacturing one drug to another (change-over)



Being carbon neutral

SAME-DAY BATCH RELEASE

Challenges

Increasing right-first-time efforts, removing paper for efficiency and sustainability, eliminating data transcriptions

Solution

A unified workflow across all QC laboratories using BIOVIA ONE Lab

Value

98% of analytical results acquired and issued automatically

Review times decreased up to 75%

Execution times decreased up to 50%

One single workflow on all QC laboratories



BIOPHARMA | END-TO-END PLATFORM

Improve Patient Outcomes by Elevating Indication and Therapeutics Knowledge and Know-How

Develop

Research & Discovery

Preclinical

Clinical Development & Supply

Supply, Manufacture & Control

Phase 1


Phase 2

Phase 3

Commercial Manufacturing



Faster to IND
Speed to Patient



Clinical Development
Patient Outcomes



Manufacturing
Right First Time & Efficient Release

